Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.

News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read the press release